Skip to content

Safety and Efficacy of Sofwave Treatment to Lift Lax Skin

Safety and Efficacy of Sofwave Treatment to Lift Lax Skin

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04829227
Enrollment
45
Registered
2021-04-02
Start date
2020-01-10
Completion date
2021-12-31
Last updated
2022-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Laxity

Keywords

Laxity Brow Lifting Skin Saggy

Brief summary

Open-label, non-randomized 2 arms prospective, multi-center, self-controlled clinical study with masked evaluation.

Detailed description

This study is a two-arm study. Eligible patients will receive 2-4 face and/or neck and/or submental or off the face (abdomen, or arms, or thighs, or Décolleté) treatments (per PI discretion, 2-12 weeks apart) using the Sofwave System. In arm 1, each investigational site would treat the full face and/or neck and/or submental zones including 1. -The forehead and temples (left and right including the peri orbital zone) to lift the eyebrows 2. The cheeks (left and right including perioral zone and nasolabial folds) 3. Submental and sides of the neck (left and right) to lift lax skin. In arm 2, each site would treat off the face areas: abdomen, or arms or thighs or Décolleté. Each patient could be assigned to both arms. Treatment may be administered after the enrollment and screening at the first visit or it may occur at a later date following the enrollment and screening activities based on site scheduling availabilities. All patients will return to the clinic for one follow up visitat3 months ± 2 weeks post last treatment (FU1) and a second optional visit at 2. 6 months ± 2 weeks post last treatment (FU2; optional). Each treatment visit will also serve as a follow up.

Interventions

DEVICESofwave

The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.

Sponsors

Sofwave Medical LTD
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
35 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy female and male subjects between the ages 35-80. 2. Non-Smoker. 3. Fitzpatrick skin type I-VI. 4. Desire to lift lax skin in the neck and submental and/or to lift the brows. 5. Able and willing to comply with all visit, treatment and evaluation schedules and requirements. 6. Able to understand and provide written Informed Consent 7. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment.

Exclusion criteria

1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding. 2. Presence of any active systemic or local infections. 3. Presence of active local skin disease that may alter wound healing. 4. Severe solar elastosis. 5. History of smoking in past 10 years. 6. History of chronic drug or alcohol abuse. 7. Excessive subcutaneous fat on the cheeks. 8. Significant scarring in the area to be treated. 9. Severe or cystic facial acne, acutance uses during past 6 months. 10. Presence of a metal stent or implant in the facial area (dental implants and/or braces are not excluded). 11. Inability to understand the protocol or to give informed consent. 12. History of cosmetic treatments in the facial area to be treated, including facial skin-tightening procedure within the 6 months ; injectable (Botox or fillers) of any type within the 6 months; ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep facial peels within the past 12 months; facelift, blepharoplasty, or brow lift (including contour threads) within the past 12 months. 13. Taking Isotretinoin or other oral retinoid within the past 6 months; taking anti-platelet or anti-coagulant within the past 2 weeks. 14. As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Design outcomes

Primary

MeasureTime frameDescription
Improvements in lifting of lax tissue3 and 6 months post last treatmentas assessed by independent masked evaluators of pre and post treatment images.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026